Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.02.038
Abstract: Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive… read more here.
Keywords: biomarker immunotherapy; tumour mutational; biomarker; burden biomarker ... See more keywords